Neonc Technologies Holdings Financial Results
NeOnc Technologies reported Q3 2026 financial results, highlighting a narrowed net loss of $4.4 million compared to $8.6 million in the prior year period. The company also noted clinical progress with positive topline Phase 2a results for its NEO100 program and a $15 million capital raise completed in September.
- Term
- Q3 2026
“The third quarter marked a period of meaningful progress for NeOnc, strengthening our clinical programs, our balance sheet and our international presence. In August, we were pleased to report positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint, an important milestone that supports the potential of our intranasal approach to directly address delivery across the blood-brain barrier, one of the greatest challenges in treating brain cancer.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
“Alongside these clinical achievements, we strengthened the financial and strategic foundation that supports them. In September, we raised $15 million from new and existing healthcare-focused institutional investors and used a portion of the proceeds to redeem all of our Series A Convertible Preferred Stock in cash, eliminating its potential dilution for our shareholders.”
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer